Leukemia Research
Volume 26, Issue 3 , Pages 311-316 , March 2002

Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs

  • H.Elizabeth Broome

      Affiliations

    • University of California, San Diego Medical Center, 200 West Arbor Drive, Mail Code 8320, San Diego, CA 92103, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-619-543-2395; Fax: +1-619-543-3730
    • ,
  • Alice L Yu

      Affiliations

    • University of California, San Diego Medical Center, 200 West Arbor Drive, Mail Code 8320, San Diego, CA 92103, USA
    • ,
  • Mitch Diccianni

      Affiliations

    • University of California, San Diego Medical Center, 200 West Arbor Drive, Mail Code 8320, San Diego, CA 92103, USA
    • ,
  • Bruce M Camitta

      Affiliations

    • Midwest Children's’ Cancer Center, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    • ,
  • Brett P Monia

      Affiliations

    • Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    • ,
  • Nicholas M Dean

      Affiliations

    • Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA

Received 19 February 2001 ,Accepted 25 June 2001.

References 

  1. Uckun FM, Yang Z, Sather H, et al.  Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood. 1997;89:3769
  2. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annual Review of Immunology. 1998;16:395
  3. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 1995;86:1903
  4. Webb A, Cunningham D, Cotter F, et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137
  5. Taylor JK, Zhang QQ, Monia BP, et al.  Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene. 1999;18:4495
  6. Norman MR, Harmon JM, Thompson EB. Use of a human lymphoid cell line to evaluate interactions between prednisolone and other chemotherapeutic agents. Cancer Research. 1978;38:4273
  7. Broome HE, Dargan CM, Krajewski S, Reed JC. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. Journal of Immunology. 1995;155:2311
  8. Chou T-C. The median-effect principle and the combination index for quantification of synergism and antagonism. In:  Chou T-C,  Rideout D editor. Synergism and Antagonism in Chemotherapy. New York: Academic Press; 1991;p. 61
  9. Schmitt E, Cimoli G, Steyaert A, Bertrand R. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Experimental Cell Research. 1998;240:107
  10. Hartmann BL, Geley S, Löffler M, et al.  Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Oncogene. 1999;18:713

PII: S0145-2126(01)00118-7

Leukemia Research
Volume 26, Issue 3 , Pages 311-316 , March 2002

Article Tools

* Image Usage & Resolution